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Background: Zinc-alpha2-glycoprotein (AZGP1, ZAG) was recently demonstrated to be an important factor in
tumor carcinogenesis. However, AZGP1 expression in hepatocellular carcinoma (HCC) and its significance remain
largely unknown.
Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was applied to determine mRNA level of
AZGP1 in 20 paired fresh HCC tissues. Clinical and pathological data of 246 HCC patients were collected.
Tissue-microarray-based immunohistochemistry (IHC) was performed to examine AZGP1 expression in HCC
samples. Relationship between AZGP1 expression and clinicopathological features was analyzed by Chi-square
test, Kaplan-Meier analysis and Cox proportional hazards regression model.
Results: AZGP1 expression was significantly lower in 80.0% (16/20) of tumorous tissues than that in the
corresponding adjacent nontumorous liver tissues (P< 0.001). Consistently, IHC data revealed that decreased
expression of AZGP1 was present in 80.1% (197/246) of HCC patient tissues (P< 0.001). Furthermore, AZGP1
expression in HCC significantly associated with several clinicopathological parameters, including serum AFP
level (P = 0.013), liver cirrhosis (P = 0.002) and tumor differentiation (P = 0.025). Moreover, HCC patients with high
AZGP1 expression survived longer, with better overall survival (P = 0.006) and disease-free survival (P = 0.025). In
addition, low AZGP1 expression associated with worse relapse-free survival (P = 0.046) and distant metastatic
progression-free survival (P = 0.036).
Conclusion: AZGP1 was downregulated in HCC and could be served as a promising prognostic marker for
HCC patients.
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Hepatocellular carcinoma (HCC), one of the most popu-
lar tumors in the whole world, is the third leading cause
of tumor mortality [1]. The incidence of HCC varies
greatly around the world, with the highest prevalence in
Southeast Asia and Africa. About 230,000 people (53%
of the world cases) in China die from HCC every year* Correspondence: yunjp@sysucc.org.cn
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reproduction in any medium, provided the or[2]. Hepatocarcinogenesis is a complex process and the
occurrence is the result of coactions of multi-factors,
such as physical condition, aflatoxin, hepatitis virus in-
fection, cirrhosis, genetic susceptibility and epigenetic
changes [3,4]. The main effective treatments of HCC
include surgery, radiofrequency, combination of che-
motherapeutics and radiotherapy recently, whereas
post-treatment relapse and metastasis are dangerous
factors of therapeutic effect [5,6]. Although the develop-
ment of multidisciplinary treatment brings us so many
advantages and disadvantages, it is urgent and necessary
to identify specific markers which could predict recur-
rence, metastasis and prognosis for patients with HCCLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are been raised to assist tumor treatment, such as
BRAF and PIK3CA [7].
Zinc-alpha2-glycoprotein (AZGP1), a 40-kDa single-
chain polypeptide assigned to the chromosome 7q22.1,
is involved in carcinogenesis and differentiation. The
structure and sequence of AZGP1 are highly homology
to major histocompatibility complex class I (MHC I)
family which may function importantly in immunity [8].
AZGP1 is a member of macroglobulin family, which is
actively involved in both inhibition of tumor growth and
proliferation [9]. AZGP1 was reported to inhibit the en-
zyme-mediated tumor invasion and activate apoptosis
though binding hydrolases [10]. AZGP1 normally dis-
tributed in human liver, prostate, breast,esophagus and
other organs [11]. AZGP1 has been reported to inhibit
the proliferation of tumor cells by down-regulating cdc2
so as to lead to a cell cycle arrest in G2/M phase [12].
Besides, the capacity of AZGP1 to inhibit TGF-
β-mediated epithelial-to-mesenchymal transdifferentia-
tion (EMT) makes it possible to inhibit tumor invasion
[13]. Apart from the above-mentioned function, there is
mounting evidence to show AZGP1 may play a part in
the expression of the immune response [8]. As the struc-
ture and sequence are highly homology to MHC class I,
AZGP1 may afford some protective effect in tumor
patients and benefit to prevent the cancer progression
[14].
Recent studies indicated that AZGP1 was differently
expressed in human tumors. For example, its expression
is increased in breast cancer, prostate cancer and lung
adenocarcinoma [14-16], but decreased in pancreatic
carcinoma and oral tumors [13,17]. Interestingly, expres-
sions of AZGP1 in cancer tissues have been demon-
strated to be connected with recurrence and metastasis
[18,19].
However, the expression of AZGP1 in HCC and its
significance is still unknown. In this study, we examined
the mRNA and protein levels of AZGP1 in HCC and
determined the relationship between AZGP1 expression
and various clinicopathologic parameters in order to sys-
tematically investigate whether AZGP1 plays a role in
HCC carcinogenesis and its clinical significance.
Materials and methods
Patients and tissue specimens
Paraffin-embedded specimens from 246 patients with
HCC between 1997 and 2001 by immunohistochemistry,
as well as clinical and pathological data, and 20 cases of
resected fresh tissues with HCC between Jan and Jul
2011 for analysis of mRNA and protein expression, were
collected from Sun Yat-Sen University Cancer Center,
Guangzhou, China. The 246 cases, with histologically con-
formed were randomly selected from 400 patients withHCC who underwent initial surgical resection and did not
receive preoperative radiotherapy or chemotherapy.
Child-Pugh classification and the 15-min retention rate
for indocyanine green (ICGR15) were essential to be con-
sidered in the preoperative assessment. The cases selected
were based on availability of 10 years’ follow-up data and
complete medical records. Patients whose cause of death
remain unknown were excluded form our study. The 246
cases aged from 14 to 78 years (mean, 48 years) include
219 males (91.3%) and 27 females (8.7%). Clinicopatholo-
gic characteristics for these patients were described in
Table 1. Tumor differentiation was assessed according to
the criteria proposed by Edmonson and Steiner [20].
Tumor stage was defined according to American Joint
Committee on Cancer/International Union Against Can-
cer tumor-node-metastasis (TNM) classification system
[21]. The use of tissues for this study was approved by
the Institute Research Medical Ethics Committee of Sun
Yat-Sen University Cancer Center and written informed
consent was obtained from each patient.
RNA preparation and quantitative real-time polymerase
chain reaction
Total RNA was extracted from 20 pairs of HCC tissues
and the adjacent non-tumorous liver tissues from 20
cases of fresh tissues with HCC using Trizol regent
(BIOO Scientific Corp., Austin, TX,USA) and cDNA
was synthesised using SuperScript RT kit (Promega,
Madison, WI, USA) according to the manufacturer's
instructions. The expression levels of AZGP1 and β-
actin were measured using SYBR green-based real-time
PCR performed on the Stratagene Mx3000P Real-Time
PCR system. The primer sequences for AZGP1 were
sense, ACGACAGTAACGGGTCTCAC and antisense,
AGGCTGGGATTTCTTTGTTGAA, whereas those for
β-actin were sense, TGGCACCCAGCACAATGAA and
antisense CTAAGTCATAGTCCGCCTAGAAGCA. The
optimised amplification protocol consisted of an initial
denaturation step of 95°C for 10 min, followed by 40
amplification cycles at 95°C for 10 s, annealing at 59°C
for 20 s and elongation at 72°C for 10 s. The fold-
changes for AZGP1 expression levels were calculated
using 2-ΔΔCt.
Western blot
The 20 pairs of fresh samples including tumor tissues
and the adjacent non-tumorous liver tissues were
homogenated in a RIPA lysis buffer, and lysates were
cleared by centrifugation (12,000 rpm) at 4°C for
30 min. The supernatant was collected and total pro-
tein (50 μg) was separated on 12% SDS-polyacrylamide
gel electrophoresis (PAGE), and electrotransferred on a
polyvinylidene difluoride (PVDF) membrane (Pall Corp.,
Port Washington, NY). After blocking non-specific
Table 1 Correlation between AZGP1 expression and clinical and pathological characters in HCC
Variable AZGP1 protein
All cases Low expression High expression χ2 P valueα
Age(years) b 0.134 0.714
48 119 46 (38.7) 73 (61.3)
≥ 48 127 52 (40.9) 75 (59.1)
Mean± SD(47.9 ± 11.8)
Gender 0.099 0.753
Female 27 10 (37.0) 17(63.0)
Male 219 88(40.2) 131(59.8)
HBsAg 0.673 0.412
Yes 213 87 (40.8) 126 (59.2)
No 33 11(33.3) 22 (66.7)
AFP (ng/ml) 6.182 0.013
≤ 20 104 32 (30.8) 72 (69.2)
> 20 142 66 (46.5) 76 (53.5)
Liver cirrhosis 9.244 0.002
Yes 177 81 (45.8) 96 (54.2)
No 69 17 (24.6) 52 (75.4)
Tumor size (cm) 0.457 0.499
≤ 5 127 48 (37.8) 79 (62.2)
> 5 119 50 (42.0) 69 (58.0)
Tumor multiplicity 0.042 0.837
Single 130 51 (39.2) 79 (60.8)
Multiple 116 47 (40.5) 69 (59.5)
Tumor differentiation 9.347 0.025
Well (I) 33 6 (18.2) 27 (81.8)
Moderate (II) 125 54 (43.2) 71 (56.8)
Poor (III) 76 35 (46.1) 41 (53.9)
Undifferentiation (IV) 12 3 (25) 9 (75)
Clinical Stage 2.154 0.541
I 16 5 (31.3) 11 (68.7)
II 93 33 (35.5) 60 (61.5)
III 106 46 (43.4) 60 (56.6)
IV 31 14 (45.2) 17 (54.8)
Vascular invasion 1.966 0.161
Yes 73 34 (46.6) 39 (53.4)
No 173 64 (37.0) 109 (63.0)
αChi-square test; b patients were divided according to the median age; AFP, alpha-fetoprotein; HBsAg, hepatitis B surface antigen; AZGP1, zinc-alpha2-glycoprotein.
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were then incubated with primary mouse monoclonal
antibodies against AZGP1 (Santa Cruz Biotechonlogy,
CA, USA, at 1:1000 dilution), and GAPDH (Santa Cruz
Biotechonlogy, CA, USA, at 1:4000 dilution) at 4°C over-
night. After washing, the membrane was then incubated
with the secondary anti-mouse antibody (Santa Cruz Bio-
technology, CA, USA) for 1 h at room temperature. The
immunoreactive signals were detected with enhanced
chemiluminescence kit (Amersham Biosciences, Uppsala,Sweden). The procedures followed were conducted in ac-
cordance with the manufacturer’s instructions.
Tissue microarray (TMA)
Tissue microarray was constructed according to the
method described previously [22]. Briefly, all samples
were fixed in formalin and embedded in paraffin. The
corresponding histological hematoxylin and eosin
(H&E)-stained sections were reviewed by two patholo-
gists to determine and mark out representative areas of
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which contained two tumor tissues and two adjacent
non-tumorous liver tissues. Each tissue core with a
diameter of 0.6 mm was punched from the marked areas
and re-embedded into a recipient paraffin arrayblock.
Multiple sections (3-μm thick) were cut and mounted
on microscope slides. After then, one section from the
tissue array block was stained with H&E and confirmed
that the punches had got the representative areas.
Immunohistochemistry
Immunohistochemical detection for AZGP1 was per-
formed using a standard two-step method. The TMA
sections were dried overnight at 37°C, deparaffinized in
xylene and hydrated through a series of graded alcohol.
Before antigen retrieval, endogenous peroxidase activity
was inhibited with 3% hydrogen peroxide for 20 min.
Then the slides were boiled in ethylene diamine tetraa-
cetic acid (EDTA; 1 mmol/L; PH 8.0) by a pressure
cooker for 5 min. After washing five times in phosphate
buffered saline (PBS; 0.01 mol/L; pH= 7.4), the slides
were preincubated with 10% normal goat serum for
30 min to reduce nonspecific antibody binding. Subse-
quently, they were incubated overnight at 4°C with the
rabbit polyclonal antibody against AZGP1 (Protein Tech
Group, Chicago, IL, USA; 1:800 dilution). After rinsing,
the slides were incubated with a secondary antibody
(Dako Corp., Glostrup, Denmark) for 1 h at room
temperature, and stained with 3, 3-diaminobenzidine tet-
rahydrochloride (DAB) after washing in PBS again. Fi-
nally, they were counterstained with Mayer's
hematoxylin, dehydrated, and mounted. Slides were
immunoreacted with PBS as the negative controls.
Known immunostaining-positive slides were used as
positive controls.
Immunohistochemistry evaluation
Semi-quantitative immunohistochemical detection was
used to determine the AZGP1 protein levels. Cytoplasm
immunoreactivity for the AZGP1 protein was scored by
evaluating the sum of positive tumor cells and the stain-
ing intensity over the total number of tumor cells. In
brief, the percent of positive cells was scored as "0" (0%),
"1" (1%-10%), "2" (11%-50%), "3" (51%-80%), "4" (81%-
100%). Intensity was scored as "0" (no staining), "1"
(weakly stained), "2" (moderately stained), and "3"
(strongly stained). Both the scores were decided under
double-blind conditions by three independent profes-
sionals. The final immunoreactive scores were deter-
mined by multiplying the intensity scores with the
extent of positivity scores of stained cells [23,24]. The
scores were then classified as follow: "-" (score 0), " + "
(score 1–4), "++" (score 5–8), and "+++"" (score 9-12).
For the purpose of statistical analysis, the cohort wasgrouped into low expression group ("-"," + ") and high ex-
pression group ("++","+++") for either 246 tumor tissues
or their adjacent non-tumorous liver tissues.
Statistical analysis
Statistical analyses were performed with the SPSS 13.0
software (SPSS, Chicago, IL, USA). The correlation be-
tween AZGP1 expression and various clinical and patho-
logical characteristics were evaluated by Paired sample t-
test. Kaplan-Meier analyses were used to analyze AZGP1
as univariate in prediction of patients’ survival. Compari-
sons of survival distributions were done with log-rank
test. The multivariate survival analyses were performed
by a stepwise Cox proportional hazard model using the
Wald statistics. P values of< 0.05 were considered
significant.
Results
The expression of AZGP1 in HCC by qRT-PCR and western
blotting
Results showed that in 16 out of 20 cases, AZGP1 mRNA
expressions in HCC tissues were noticeably lower than
those in the adjacent non-tumorous liver tissues, as deter-
mined by qRT-PCR. As depicted in Figure 1A, mRNA level
of AZGP1 in HCC tissue was on average 15.5-fold lower
than that in corresponding adjacent liver tissue. There was
significant difference in the average level of AZGP1 be-
tween tumor tissues and non-tumorous tissues (P=0.001).
To examine the protein level of AZGP1 in HCC, western
blot was performed (Figure 1B). The ratio of AZGP1 ex-
pression in non-tumorous tissues to that in tumorous tis-
sues was calculated. Results showed that AZGP1
expression in tumorous tissues was on average 1.55-fold
lower than that in the paired non-tumorous tissues.
The expression of AZGP1 in HCC by
immunohistochemistry
The protein status of AZGP1 was further examined by
TMA and IHC, using 246 pairs of HCC and adjacent
non-tumorous liver tissues (Figure 2). Results indicated
that reduced expression of AZGP1 presented in 80.1% of
HCC tissues (Figure 2A~C). Kruskal-Wallis's analysis
revealed that AZGP1 expression was significantly
decreased by more than 2-fold in tumorous tissues,
compared to that in adjacent non-tumorous liver tissues
(P <0.001, t= -6.502) (Figure 2D).
The relationship between AZGP1 expression and
clinicopathological parameters
To investigate the relationship between AZGP1 expres-
sion and clinicopathological parameters in 246 cases
with HCC, these cases were first divided into two sub-
groups: “Low AZGP1 expression” and “High AZGP1 ex-
pression” as defined in the Immunohistochemistry
Figure 1 The expression of AZGP1 in HCC by qRT-PCR and Western blotting. A. Expression of AZGP1 mRNA in HCC tissues (T) and the
adjacent non-tumorous liver tissues (N) (n = 20) was examined by qRT-PCR. Data were mean± SD of three independent experiments. *, P< 0.05
and **, P< 0.001 versus to the adjacent non-tumorous liver tissues. B. Expression of AZGP1 protein in HCC tissues (T) and the adjacent non-
tumorous liver tissues (N) (n = 20) was examined by Westen blotting. Ratio of AZGP1 expression in N to T was indicated.
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tions were found between AZGP1 expression and three
parameters including serum AFP levels (P= 0.013), cir-
rhosis (P= 0.002) and tumor differentiation (P= 0.017).
Patients with low AZGP1 expression had a higher ten-
dency to have high level of serum AFP, liver cirrhosis,
and poor tumor differentiation. There were no statistical
connections between AZGP1 expression and the rest
clinicopathological parameters, such as patient age,Figure 2 The protein expression of AZGP1 in HCC by immunohistoch
cytoplasm within tumor cells. A. Negative staining of AZGP1 was detected
AZGP1. C. Strong staining of AZGP1 was observed in 95% of the adjacent
score of AZGP1 in HCC tissues (T) and the adjacent non-tumorous liver tissgender, HBsAg, tumor size, tumor multiplicity, clinical
stage and vascular invasion (P> 0.05, Table 1).
The association of low AZGP1 expression in HCC with
poor survival in patient
The association between AZGP1 expression in HCC
and the survival time of selected patients was ana-
lyzed with Kaplan-Meier survival analysis (Figure 3).
The median overall survival (OS) time of low AZGP1emistry. The immunoreactivity was primarily observed in the
in HCC case (#136) B. HCC case (#57) showed weak expression of
non-tumorous liver tissues. D. The box plot showed the mean staining
ues (N) (P< 0.001, t= -6.502).
Figure 3 (See legend on next page.)
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Figure 3 Survival analysis of AZGP1 expression in HCC. A, B. Probability of OS (A) and DFS (B) of total HCC patients. C, D. Probability of OS
(C) and DFS (D) of well differentiated (grade I + II) HCC patients. E, F. Probability of OS (E) and DFS (F) of positive cirrhosis HCC patients.
Huang et al. Journal of Translational Medicine 2012, 10:106 Page 7 of 10
http://www.translational-medicine.com/content/10/1/106expression group was 34.1 months, significantly
shorter than that of high AZGP1 expression group
(72 months) (P = 0.006, Figure 3A). Furthermore, the
median disease-free survival (DFS) time of low
AZGP1 expression group was remarkably shorter than
that of high AZGP1 expression group (P=0.025, Figure 3B).
Statistically, the 5-year OS rate and DFS rate of low AZGP1
expression group were 31.0% and 22.5%, respectively,
whereas they were 44.8% and 32.0%, respectively, in high
AZGP1 expression group. Moreover, we stratifiedly ana-
lyzed the subtype of patient with well tumor differentiation
(OS: P=0.001, Figure 3C; DFS: P=0.017, Figure 3D) and
liver cirrhosis (OS: P=0.014, Figure 3E; DFS: P=0.042,
Figure 3F). Results showed that HCC patients with high
AZGP1 expression survived longer.
Univariate analysis was also performed on 11 clinial-
pathological parameters that may affect postoperative
survival of HCC patients (Table 2). Results indicated that
AZGP1 expression, as well as serum AFP level, tumor
size, tumor multiplicity, tumor differentiation, clinical
stage and vascular invasion, was one of the factors that
are responsible for efficacy of surgical treatment in HCC
patient, by showing that AZGP1 expression was signifi-
cantly correlated to OS (P= 0.007) and DFS (P= 0.033)
of HCC patients. Next, we subjected the statistically sig-
nificant parameters to Cox proportional hazards regres-
sion model to evaluate the significance of AZGP1
expression in HCC prognosis. Results suggested AZGP1
expression was not an effective independent prognostic
factor (Table 3).Table 2 Univariate analysis of different prognostic factors in
Variable Overall survival rate (%)
HR (95% CI) P v
Age (years) 1.037(0.674-1.596) 0.86
Gender 0.74(0.356-1.536) 0.41
HBsAg 0.776(0.421-1.431) 0.41
AFP (ng/ml) 3.408(2.038-5.698) < 0
Liver cirrhosis 1.087(0.672-1.760) 0.73
Tumor size (cm) 2.409(1.532-3.790) < 1
Tumor multiplicity 3.233(2.022-5.168) < 0
Tumor differentiation 1.649(1.246-2.183) < 0
Clinical stage 3.079(2.269-4.178) < 0
Vascular invasion 4.704(3.027-7.311) < 0
AZGP1 0.553(0.359-0.851) 0.0
CI, confidence interval; HR, hazard ratio; AFP, alpha-fetoprotein; HBsAg, hepatitis B sAssociation of high AZGP1 expression with long period of
recurrence and distant metastasis
We further assessed whether AZGP1 expression in HCC
was related to the risk of recurrence and metastasis. Sur-
vival analysis indicated that AZGP1 expression was
negatively associated with the risk of clinical recurrence
(HR=0.698, 95% CI= 0.488 to 0.999, P=0.046; Figure 4A)
and distant metastatic progression (HR=0.679, 95% CI=
0.471 to 0.981, P=0.036; Figure 4B). This may suggest
AZGP1 may be involved in tumor recurrence and
metastasis.
Discussion
Recently, it has been shown that AZGP1 plays a crucial
role in carcinogenesis and is of clinicopathologic signifi-
cance in human cancers [8,25-28]. In the present study,
AZGP1 expression was found to be decreased in HCC
tissues at both mRNA and protein levels. Moreover, low
expression of AZGP1 was notably more prevalent in
patients with poor tumor differentiation, serious liver
cirrhosis, high serum AFP level and short survival time.
Our results may suggest AZGP1 as a promising novel
prognostic biomarker for HCC.
Recently reports showed AZGP1 was overexpressed in
some tumors, but lost or reduced in other tumors [13,17].
Although the exact mechanism remains elusive, expres-
sion of AZGP1 is partly attributed to the acetylation status
of histone which regulates gene activity by changing the
conformation of chromatin. Daniel and colleagues found
that AZGP1 was upregulated in lung adencarcinoma due246 HCC patients
Disease-free survival rate (%)




.001 2.088(1.499-2.909) < 0.001
3 1.174(0.813-1.694) 0.392
0.001 1.806(1.311-2.488) < 0.001
.001 1.972(1.429-2.722) < 0.001
.001 1.621(1.314-2.000) < 0.001
.001 1.785(1.457-2.187) < 0.001
.001 2.393(1.714-3.341) < 0.001
07 0.706(0.513-0.972) 0.033
urface antigen; AZGP1, zinc-alpha2-glycoprotein.
Table 3 Multivariate analysis of overall and disease-free
survival rates of HCC patients
Variable β SE Hazard ratio (95%CI) P value
Overall sruvival
Clinical stage 1.382 0.468 3.982 (1.590-9.974) 0.003
Vascular invasion 0.895 0.258 2.448 (1.477-4.059) 0.001
AFP 0.781 0.273 2.184 (1.279-3.730) 0.004
Tumor differentiation 0.599 0.299 0.550 (0.306-0.988) 0.045
Tumor multiplicity 0.438 0.283 1.549 (0.889-2.698) 0.122
AZGP1 -0.321 0.231 0.725 (0.461-1.141) 0.164
Tumor size 0.319 0.245 1.376 (0.852-2.224) 0.192
Disease-free survival
Relapse 1.252 0.167 3.499 (2.522-4.854) < 0.001
Vascular invasion 0.775 0.206 2.171 (1.449-3.253) < 0.001
AFP 0.533 0.173 1.705 (1.215-2.392) 0.002
Tumor differentiation 0.521 0.232 0.594 (0.377-0.936) 0.025
Tumor size 0.361 0.18 1.435 (1.009-2.041) 0.044
Tumor multiplicity 0.427 0.238 1.533 (0.962-2.443) 0.072
AZGP1 -0.211 0.166 0.810 (0.585-1.121) 0.204
Clinical stage 0.188 0.286 1.207 (0.689-2.115) 0.510
β, Regression coefficient; SE, standard error; CI, confidence interval; AFP, alpha-
fetoprotein; AZGP1, zinc-alpha2-glycoprotein.
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AZGP1 in pancreatic ductal adenocarcinoma is lost owing
to histone deacetylation [14]. However, whether histone
deacetylation contributes to the decreased expression of
AZGP1 found in this study requires further investigation.
Reports demonstrated that poorly differentiated tumors
expressed less AZGP1 than well differentiated tumors in
most of popular human tumors, such as breast cancer,Figure 4 Association of AZGP1 with HCC patients’ recurrence and me
expression. B. Metastasis-free survival in patients stratified by AZGP1 expresprostate cancer, oral squamous cell carcinomas, epidermal
tumors, sweat gland tumors, pancreatic cancer and cer-
vical cancer [13,15,16,26-30]. Interestingly, complicated
relationships between AZGP1 expression and clinical
stages of cancer patients are common. AZGP1 was stage-
dependent increased in the urinary bladder cancer [25].
However, an inverse association between AZGP1 expres-
sion with tumor stage was found in prostate cancer [29].
In addition, AZGP1 expression is correlated positively to
leptin receptor and negatively to adiponectin receptor and
estrogen receptor in breast cancer tissue. In our study,
low level of AZGP1 appeared to be significantly associated
with poorer differentiation. Although the percentage of
patients with HBV infection was greater and the ages of
patients were younger in our study, when compared to
patients with HCC in Western countries or Japan, our find-
ings suggest that loss or decrease expression of AZGP1
may promote HCC progression. Further studies should be
needed to examine the role of AZGP1 in patients with
HCV-related HCC or without hepatitis viral infection.
AZGP1 is considered as a potential biomarker of various
tumors. AZGP1 was also proposed as predictor for breast
cancer due to its elevated expression in cancer and normal
epithelial adjacent tissues but not in normal tissue of
healthy women [31]. AZGP1 was reported to be a diag-
nostic marker for cancer cachexia due to its high expres-
sion [32,33]. In prostate cancer, AZGP1 could be served
as a potential serum maker, being expressed in malig-
nant prostatic epithelium [16]. However, relationship
between AZGP1 and HCC has not been studied. In the
present study, we showed that AZGP1 expression was
decreased by over 2 folds in HCC tissues, compared to
that in the adjacent non-tumorous liver tissues. Thesetastasis. A. Recurrence-free survival in patients stratified by AZGP1
sion.
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give a selective advantage in the HCC tumor progression.
AZGP1 has been identified as a predictor of prognosis
in some tumors. In lung adenocarcinoma and prostate
cancer, patients with high levels of AZGP1 had better sur-
vival than those with low levels of AZGP1 [14,29,34]. Ab-
sent or weak AZGP1 expression is reported to be
associated with shorter recurrence-free and metastasis-
free survival of prostate cancer patients [18,19]. In our
study, HCC patients with low AZGP1 expression had
shorter survival time. Cox regression analysis indicated
that AZGP1 might be one of the factors that affect HCC
patients' survival. High AZGP1 expression was associated
with significantly longer period of clinical recurrence and
distant metastasis. These observations suggest that it
might be of significance to utilize the expression of
AZGP1 as a preliminary diagnostic approach to distin-
guish HCC from non-tumourous liver disease, and that
more attention should be paid to HCC patients with
decreased AZGP1 expression during and after the process
of therapy. However, it is noteworthy that further investi-
gation and validation are required before a clinical prac-
tice. Collectively, these data suggest that AZGP1 may be a
promising prognostic marker for HCC.
Conclusion
In summary, our study demonstrated that AZGP1 was fre-
quently decreased in HCC. Low expression of AZGP1 could
be served as a tumor biomarker for poor differentiation and
a predictor for poor prognosis of HCC patients.
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